# Treatment methods for drug-resistant tuberculosis
Drug-resistant tuberculosis requires longer, more intensive treatment than drug-susceptible tuberculosis. The choice of medicines depends on which resistance is present and how severe it is. Below are the main treatment groups as they are currently applied.
First-generation anti-tuberculosis agents
These agents form the basis of many treatment regimens, also in cases of resistance, although their effectiveness depends on the resistance pattern.
**Rifampicin**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Rifampicin is an antibiotic that acts on the bacterial cell wall. In drug-resistant tuberculosis it is used only if susceptibility is demonstrated, or in certain forms of resistance. It works by blocking RNA synthesis in the mycobacterium. Known side effects are liver inflammation, rash and digestive problems. In rare cases allergic reactions occur.
**Isoniazid**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Isoniazid is effective against dormant and multiplying bacteria. It also works via inactivation of cell wall components. This agent can cause nerve damage (especially in case of vitamin deficiency), liver damage and skin reactions. Like rifampicin, it is used in drug-resistant tuberculosis only if susceptibility is established.
**Ethambutol**
ProveniIncluded in official guidelines, or approved by EMA or FDA
This agent inhibits the production of certain lipid-like substances in the bacterial cell wall. It is used less often in highly resistant forms, but remains part of some regimens. Known side effects are vision problems (especially color vision), headache and gout. It can also cause nerve damage.
Second-generation anti-tuberculosis agents
These are added when first-generation agents are not effective or the resistance pattern requires it. They are usually combined with other agents.
**Fluoroquinolones (moxifloxacin, levofloxacin)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Fluoroquinolones are broad-spectrum antibiotics that inhibit DNA gyrase in the bacterium. They are an important pillar in the treatment of drug-resistant tuberculosis, especially in regimens for moderately resistant forms. Side effects include digestive problems, nerve damage in feet and legs (especially with long-term use), insomnia and in rare cases muscle rupture. They can also cause bone inflammation, especially in younger people.
**Bedaquiline**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Bedaquiline is a newer agent that blocks ATP synthase in the mycobacterium. This interrupts the bacterium's energy supply. It is widely used in modern regimens for extensively drug-resistant tuberculosis. Side effects include heart rhythm disturbances (requiring monitoring), liver damage, joint pain and gastrointestinal disorders. The agent requires careful monitoring of heart function.
**Linezolid**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Linezolid inhibits protein production in the bacterium. It is effective against extensively drug-resistant forms and is particularly used in long-term regimens. Side effects are nerve damage (especially in feet and legs, sometimes permanent), blood cell reductions (especially platelets and red cells), nausea and abdominal pain. It requires regular blood work monitoring due to the risk of anemia. Because nerve damage can increase with longer duration of use, treatment duration is usually limited.
**Clofazimine**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Clofazimine is an older agent that is primarily used in regimens for extensively drug-resistant tuberculosis. It works via oxidative stress in the bacterium. It causes red to brown discoloration of the skin, which is reversible but can be very visible. It also causes abdominal pain, nausea and diarrhea, especially in the first months. It is absorbed much more slowly than other agents.
**Delamanid**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Delamanid activates mycobacteria with low metabolism (non-multiplying bacteria). It is widely used in modern short-course regimens for highly resistant tuberculosis. Side effects include heart rhythm disturbances (for which monitoring is important), nerve damage, headache and digestive problems. It also requires ECG monitoring.
Under-investigation and not yet standard regimens
**Lipranoil/TB Alliance drugs**
ResearchediPositive results in clinical studies, not yet standard treatment
New drugs are being developed that target different points in bacterial cell wall construction. Some of these are in later investigation phases. The aim is to shorten treatments and reduce side effects. These are not yet widely available.
**Host-directed therapies**
ResearchediPositive results in clinical studies, not yet standard treatment
Research is ongoing into drugs that do not attack the bacterium itself, but strengthen the patient's immune system. This can be done by modulating inflammatory markers or strengthening certain immune pathways. This research is still in early phases, but may offer future perspective.
**Nanoparticles and advanced formulation**
ExperimentaliOngoing in study setting, outcome still unknown
Research into antibiotic substances incorporated into nanoparticles or specially packaged could provide better penetration into inflamed lung tissue. This is mainly ongoing in laboratories and animal models; clinical application is still far away.
Supportive drugs
**Vitamin B6 (pyridoxine)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
This vitamin is given to prevent nerve damage caused by isoniazid and fluoroquinolones. It acts as a cofactor for nerve function.
**Gastric protection (proton pump inhibitor)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Because long-term anti-tuberculosis drugs can cause gastric inflammation, gastric protection is usually included in the regimen. This protects the stomach lining.
Forms of resistance and regimen adjustment
**Multidrug-resistant tuberculosis (MDR-TB)**
This is tuberculosis with resistance to rifampicin and isoniazid. Standard regimens usually combine fluoroquinolones with bedaquiline, linezolid or clofazimine, depending on availability and patient situation. Treatment duration is usually 18–24 months.
**Extensively drug-resistant tuberculosis (XDR-TB)**
This is tuberculosis with resistance to rifampicin, isoniazid and fluoroquinolones. Modern regimens use bedaquiline, delamanid, linezolid and clofazimine in combination. Some regimens are shorter than in the past (around 18–20 months), thanks to better drug combinations. Other regimens are longer depending on the individual.
**Totally drug-resistant tuberculosis (TDR-TB)**
This is tuberculosis with resistance to nearly all standard drugs. Treatment is more complex and requires combination of multiple less commonly used drugs, sometimes on investigational or compassionate grounds.
Combination and duration of treatment
Anti-tuberculosis drugs are always given in combination to prevent resistance development. A typical modern regimen for highly resistant tuberculosis may consist of 3–5 medicines at the same time, given in different phases. The intensive phase (first 2–6 months, depending on regimen) usually contains multiple drugs. A continuation phase may involve ongoing combination until the total treatment regimen is complete.
Discontinuation of drugs is gradual and according to established regimen, never at the patient's initiative.
Special considerations: TB/HIV and TB/diabetes
Patients with resistant tuberculosis and HIV require special attention. Some anti-tuberculosis drugs do not work well with HIV medicines (antiretroviral therapy). When tuberculosis and diabetes are combined, both diseases can worsen each other and certain treatment choices may be limited.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._